Telangiectasia (generalized essential telangiectasia)
Are You Confident of the Diagnosis?
What you should be alert for in the history
Widespread symmetrical cutaneous telangiectasias can be seen in plaque-like, macular, retiform, annular, sheet-like, or net-like patterns. They are usually asymptomatic; however, some individual lesions can cause tingling, burning, or numbness.
Characteristic findings on physical examination
Characteristic findings include widespread cutaneous telangiactasias that are pink or red in color and easily blanched with rapid refilling (
Generalized essential telangiectasia. (Courtesy of Bryan Anderson, MD)
Telangiactasias favor lower extremities and are symmetrical. They are usually permanent and can progress, become more prominent with dependent positioning, and occur on mucous membranes.
There is an absence of concurrent epidermal and dermal changes, e.g. purpura, atrophy, depigmentation, or follicular involvement, and an absence of systemic symptoms or concurrent diseases.
Expected results of diagnostic studies
Laboratory studies, including coagulation, are usually unremarkable.
Histopathology shows telangiectatic vessels in the reticular and papillary dermis; as well as a paucity of inflammation.
Angiokeratoma corporis diffusum (Fabry syndrome) - presents early in life (inborn error of metabolism, X-linked), lesions are hyperkeratotic with lack of blanching
Cutaneous collagenous vasculopathy - may be clinically identical; however, collagen is appreciated around the postcapillary venules histologically
Who is at Risk for Developing this Disease?
There is a wide age distribution, with a median age of onset of 38 years.
Telangiectasias have a female predominance and a Caucasian predominance. Familial cases with an autosomal dominant inheritance pattern have been described
What is the Cause of the Disease?
The etiology is unknown. A role for sun exposure has been suggested.
The pathophysiology includes widespread dilation of dermal vessels.
Systemic Implications and Complications
Telangiectasias are usually asymptomatic; there was one case report of associated gastrointestinal (GI) bleeding.
Treatment is usually unnecessary. The lesions are often refractory to hemoglobin-targeting laser therapy, especially those localized to the lower extremities; moreover, given the widespread distribution, this is usually impractical.
Sclerotherapy is contraindicated due to the risk of worsening exisiting lestions and/or creating new ones.
Optimal Therapeutic Approach for this Disease
Reassurance is key. Monitor for possibility of internal bleeding, although this is an exceedingly rare complication.
Treatment is usually unnecessary; however, hemoglobin-targeting laser therapy can be considered, especially for facial lesions. Sclerotherapy is contraindicated.
Reassurance is key. Treatment is usually unnecessary. There is a low risk for internal bleeding.
Unusual Clinical Scenarios to Consider in Patient Management
There was one case report of associated GI bleeding. Systemic complications are very rare.
What is the Evidence?
Checketts, SR. "Generalized essential telangiectesia in the presence of gastrointestinal bleeding". J Amer Acad Derm. vol. 37. 1997. pp. 321-5.(A case report and review of the literature that discusses the clinical features of generalized essential telangiectesia (GET), and the possibility of rare complications such as GI bleeding)
Green, D. "Generalized essential telangiectasia".(A basic review of the clinical features and management of GET)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy